Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaMedica TherapeuticsDMAC +0.29%32 Cash-to-Debt is 235.16 as of Jun. 2026, which is 3% above its 10-year median of 228.98. GuruFocus rates DMAC with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,400 Biotechnology companies, DiaMedica Therapeutics ranks better than 82.29% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. DiaMedica Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 235.16.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, DiaMedica Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for DiaMedica Therapeutics's Cash-to-Debt or its related term are showing as below:
DMAC'
s Cash-to-Debt Range Over the Past 10 Years
Min: 44.26 Med: 228.98 Max: No Debt
Current: 235.16
During the past 13 years, DiaMedica Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 44.26. And the median was 228.98.
DMAC's Cash-to-Debt is ranked better than 82.29% of 1400
companies
in the Biotechnology industry
Industry Median: 6.21
vs DMAC: 235.16
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
DiaMedica Therapeutics Cash-to-Debt Related Terms
DiaMedica Therapeutics Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, DiaMedica Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DiaMedica Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where DiaMedica Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DiaMedica Therapeutics (DMAC) has a Cash-to-Debt of 235.16 as of Jun. 2026. This is near median its historical median of 228.98. Over the past decade, DiaMedica Therapeutics' Cash-to-Debt has ranged from 44.26 to 10,000.00. According to the industry distribution chart, DiaMedica Therapeutics ranks #248 out of 1400 companies in the Biotechnology industry, placing it in the top 17.7%.
Is DiaMedica Therapeutics' Cash-to-Debt too high?
DiaMedica Therapeutics' current Cash-to-Debt of 235.16 is near median its 10-year median of 228.98. Over the past 10 years, this metric has ranged from a low of 44.26 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.21. DiaMedica Therapeutics' value of 235.16 is 3686.8% above this industry median. Based on the distribution chart, DiaMedica Therapeutics ranks #248 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, DiaMedica Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Cash-to-Debt compare to XFOR and IKT?
According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #248 out of 1400 companies for Cash-to-Debt. This places DiaMedica Therapeutics in the top 18% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.21. DiaMedica Therapeutics' value of 235.16 is 3686.8% above this benchmark. Historically, DiaMedica Therapeutics' own Cash-to-Debt has ranged from 44.26 to 10,000.00 over the past decade. While the company's 10-year median is 228.98 vs. the industry median of 6.21, DiaMedica Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.21, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DiaMedica Therapeutics's current Cash-to-Debt of 235.16 is 3686.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DiaMedica Therapeutics's current Cash-to-Debt is 235.16, which is near median its own 10-year median of 228.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Cash-to-Debt of 235.16. The current Cash-to-Debt is 235.16, which is near median its 10-year median of 228.98 and 3686.8% above the Biotechnology industry median of 6.21. DiaMedica Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Cash-to-Debt is 235.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
32GF Score
Get the complete analysis for DMAC
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMAC has been successfully added to your 
